Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.

Kato, Motoyasu; Mori, Mikiko; Miura, Keita; Asao, Tetsuhiko; Motomura, Hiroaki; Nishino, Koichi; Ko, Ryo; Koyama, Ryo; Hayashi, Takuo; Takahashi, Kazuhisa

Kato, Motoyasu; Mori, Mikiko; Miura, Keita; Asao, Tetsuhiko; Motomura, Hiroaki; Nishino, Koichi; Ko, Ryo; Koyama, Ryo; Hayashi, Takuo; Takahashi, Kazuhisa.

Affiliation

Kato M; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Mori M; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Miura K; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Asao T; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Motomura H; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Nishino K; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Ko R; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Koyama R; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Hayashi T; Department of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Takahashi K; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Thorac Cancer ; 12(22): 3076-3079, 2021 11.

Article in En | MEDLINE | ID: mdl-34617405

Subject(s)

Adenocarcinoma of Lung/drug therapy; Antibodies, Monoclonal, Humanized/adverse effects; Antibodies, Monoclonal, Humanized/therapeutic use; Carcinoma, Non-Small-Cell Lung/drug therapy; Lung Diseases, Interstitial/chemically induced; Lung Neoplasms/drug therapy; Adenocarcinoma of Lung/pathology; Adrenal Cortex Hormones/therapeutic use; Aged, 80 and over; Antineoplastic Agents, Immunological/adverse effects; Antineoplastic Agents, Immunological/therapeutic use; Carcinoma, Non-Small-Cell Lung/pathology; Humans; Lung Neoplasms/pathology; Male

Key words

drug-induced interstitial pneumonia; immune checkpoint inhibitors; immune-related adverse event; non-small cell lung carcinoma; pembrolizumab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lung Diseases, Interstitial / Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / Adenocarcinoma of Lung / Lung Neoplasms Limits: Aged80 / Humans / Male Language: En Journal: Thorac Cancer Year: 2021 Document type: Article

Fulltext

XML

PubMed Links

Search on Google